Cargando…

Prolactin and total lactogenic hormone measured by microbioassay and immunoassay in breast cancer.

Basal prolactin (PRL) and total lactogenic hormone (TLH) levels were measured using a new microbioassay (BA) and conventional immunoradiometric assay (IRMA) in patients with breast cancer and compared to an age-matched control group. No significant differences were found using the IRMA, but BA lacto...

Descripción completa

Detalles Bibliográficos
Autores principales: Maddox, P. R., Jones, D. L., Mansel, R. E.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1992
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977614/
https://www.ncbi.nlm.nih.gov/pubmed/1558804
_version_ 1782135299591110656
author Maddox, P. R.
Jones, D. L.
Mansel, R. E.
author_facet Maddox, P. R.
Jones, D. L.
Mansel, R. E.
author_sort Maddox, P. R.
collection PubMed
description Basal prolactin (PRL) and total lactogenic hormone (TLH) levels were measured using a new microbioassay (BA) and conventional immunoradiometric assay (IRMA) in patients with breast cancer and compared to an age-matched control group. No significant differences were found using the IRMA, but BA lactogenic levels were significantly elevated in breast cancer patients compared controls, leading to a markedly elevated BA/IRMA ratio for both PRL (2.7 vs 1.4, P less than 0.0001) and TLH (2.8 vs 1.4, P less than 0.0001) which was greatest for postmenopausal women. Using the mean +2 standard deviations as the upper limit of normal, there was no significant difference between breast cancer patients and controls for IRMA, but BA and BA/IRMA PRL levels were elevated in 42% and 61% of the patients, respectively. There was a weak negative correlation of BA and IRMA PRL with age for normals (r = -0.53 for both) but no correlation was evident for breast cancer patients (r = 0.06 and -0.13, respectively) implying a sustained absolute and relative bioactive hyperprolactinaemia at all ages. These results show increased lactogenic bioactivity in breast cancer and suggest that different forms of bioactive prolactin undetected by IRMA (or enhancing serum factors) are present in the sera of these patients.
format Text
id pubmed-1977614
institution National Center for Biotechnology Information
language English
publishDate 1992
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19776142009-09-10 Prolactin and total lactogenic hormone measured by microbioassay and immunoassay in breast cancer. Maddox, P. R. Jones, D. L. Mansel, R. E. Br J Cancer Research Article Basal prolactin (PRL) and total lactogenic hormone (TLH) levels were measured using a new microbioassay (BA) and conventional immunoradiometric assay (IRMA) in patients with breast cancer and compared to an age-matched control group. No significant differences were found using the IRMA, but BA lactogenic levels were significantly elevated in breast cancer patients compared controls, leading to a markedly elevated BA/IRMA ratio for both PRL (2.7 vs 1.4, P less than 0.0001) and TLH (2.8 vs 1.4, P less than 0.0001) which was greatest for postmenopausal women. Using the mean +2 standard deviations as the upper limit of normal, there was no significant difference between breast cancer patients and controls for IRMA, but BA and BA/IRMA PRL levels were elevated in 42% and 61% of the patients, respectively. There was a weak negative correlation of BA and IRMA PRL with age for normals (r = -0.53 for both) but no correlation was evident for breast cancer patients (r = 0.06 and -0.13, respectively) implying a sustained absolute and relative bioactive hyperprolactinaemia at all ages. These results show increased lactogenic bioactivity in breast cancer and suggest that different forms of bioactive prolactin undetected by IRMA (or enhancing serum factors) are present in the sera of these patients. Nature Publishing Group 1992-03 /pmc/articles/PMC1977614/ /pubmed/1558804 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Maddox, P. R.
Jones, D. L.
Mansel, R. E.
Prolactin and total lactogenic hormone measured by microbioassay and immunoassay in breast cancer.
title Prolactin and total lactogenic hormone measured by microbioassay and immunoassay in breast cancer.
title_full Prolactin and total lactogenic hormone measured by microbioassay and immunoassay in breast cancer.
title_fullStr Prolactin and total lactogenic hormone measured by microbioassay and immunoassay in breast cancer.
title_full_unstemmed Prolactin and total lactogenic hormone measured by microbioassay and immunoassay in breast cancer.
title_short Prolactin and total lactogenic hormone measured by microbioassay and immunoassay in breast cancer.
title_sort prolactin and total lactogenic hormone measured by microbioassay and immunoassay in breast cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977614/
https://www.ncbi.nlm.nih.gov/pubmed/1558804
work_keys_str_mv AT maddoxpr prolactinandtotallactogenichormonemeasuredbymicrobioassayandimmunoassayinbreastcancer
AT jonesdl prolactinandtotallactogenichormonemeasuredbymicrobioassayandimmunoassayinbreastcancer
AT manselre prolactinandtotallactogenichormonemeasuredbymicrobioassayandimmunoassayinbreastcancer